参考文献/References:
[1] Yarmohammadi F,Rezaee R,Haye AW,et al. Endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity may be therapeutically targeted by natural and chemical compounds:a review[J].?Pharmacol Res,2021,164:105383.
[2] Sawicki KT,Sala V,Prever L,et al. Preventing and treating anthracycline cardiotoxicity :new insights[J]. Annu Rev Pharmacol Toxicol,2021,61:309-332.
[3] Chen Y,Shi S,Dai Y. Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy[J]. Biomed Pharmacother,2022,156:113903.
[4] Rocca C,Soda T,de Francesco EM,et al.?Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer[J]. J Transl Med,2023,21(1):635.
[5] Zhou H,Ren J,Toan S,et al. Role of mitochondrial quality surveillance in myocardial infarction:from bench to bedside[J].?Ageing Res Rev,2021,66:101250.
[6] Huang J,Wu R,Chen L,et al. Understanding anthracycline cardiotoxicity from mitochondrial aspect[J]. Front Pharmacol,2022,13:811406.
[7] Chen L,Qin Y,Liu B,et al. PGC-1α-mediated mitochondrial quality control:molecular mechanisms and implications for heart failure[J].?Front Cell Dev Biol,2022,10:871357.
[8] Li W,Cao J,Wang X,et al. Ferruginol restores SIRT1-PGC-1α-mediated mitochondrial biogenesis and fatty acid oxidation for the treatment of DOX-induced cardiotoxicity[J].?Front Pharmacol,2021,12:773834.
[9] Zhang S,Liu X,Bawa-Khalfe T,et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J].?Nat Med,2012,18(11):1639-1642.
[10] Schank M,Zhao J,Wang L,et al. Telomeric injury by KML001 in human T cells induces mitochondrial dysfunction through the p53-PGC-1α pathway[J]. Cell Death Dis,2020,11(12):1030.
[11] Tang H,Tao A,Song J,et al. Doxorubicin-induced cardiomyocyte apoptosis:role of mitofusin 2[J]. Int J Biochem Cell Biol,2017,88:55-59.
[12] Catanzaro MP,Weiner A,Kaminaris A,et al. Doxorubicin-induced cardiomyocyte death is mediated by unchecked mitochondrial fission and mitophagy[J]. FASEB J,2019,33(10):11096-11108.
[13] Aung LHH,Li R,Prabhakar BS,et al. Knockdown of Mtfp1 can minimize doxorubicin cardiotoxicity by inhibiting Dnm1l-mediated mitochondrial fission[J].?J Cell Mol Med,2017,21(12):3394-3404.
[14] Li J,Li Y,Jiao J,et al. Mitofusin 1 is negatively regulated by microRNA 140 in cardiomyocyte apoptosis[J]. Mol Cell Biol,2014,34(10):1788-1799.
[15] ]Ao X,Ding W,Li X,et al. Non-coding RNAs regulating mitochondrial function in cardiovascular diseases [J]. J Mol Med (Berl),2023,101(5):501-526.
[16] ]Ding M,Shi R,Cheng S,et al. Mfn2-mediated mitochondrial fusion alleviates doxorubicin-induced cardiotoxicity with enhancing its anticancer activity through metabolic switch[J].?Redox Biol,2022,14:102315.
[17] Samant SA,Zhang HJ,Hong Z,et al. SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress[J].?Mol Cell Biol,2014,34(5):807-819.
[18] ]Ajoolabady A,Aslkhodapasandhokmabad H,Aghanejad A,et al. Mitophagy receptors and mediators:therapeutic targets in the management of cardiovascular ageing[J]. Ageing Res Rev,2020,62:101129.
[19] Tang C,Cai J,Yin XM,et al. Mitochondrial quality control in kidney injury and repair[J]. Nat Rev Nephrol,2021,17(5):299-318.
[20] Ling G,Wang X,Tan N,et al. Mechanisms and drug intervention for doxorubicin-induced cardiotoxicity based on mitochondrial bioenergetics[J].?Oxid Med Cell Longev,2022,2022:7176282.
[21] Roca-Portoles A,Tait SWG. Mitochondrial quality control:from molecule to organelle[J].?Cell Mol Life Sci,2021,78(8):3853-3866.
[22] ]Hoshino A,Mita Y,Okawa Y,et al. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart[J].?Nat Commun,2013,4:2308.
[23] Gambardella J,Santulli G,Fiordelisi A,et al. Infiltrating macrophages amplify doxorubicin-induced cardiac damage:role of catecholamines[J].?Cell Mol Life Sci,2023,80(11):323.
[24] Gao B,Yu W,Lv P,et al. Parkin overexpression alleviates cardiac aging through facilitating K63-polyubiquitination of TBK1 to facilitate mitophagy [J].?Biochim Biophys Acta Mol Basis Dis,2021,1867(1):165997.
[25] Dhingra R,Guberman M,Rabinovich-Nikitin I,et al. Impaired NF-κB signalling underlies cyclophilin D-mediated mitochondrial permeability transition pore opening in doxorubicin cardiomyopathy[J]. Cardiovasc Res,2020,116(6):1161-1174.
[26] Wang P,Wang L,Lu J,et al. SESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial function[J]. J Mol Cell Cardiol,2019,133:125-137.
[27] Zhang Y,Weng J,Huan L,et al. Mitophagy in atherosclerosis:from mechanism to therapy[J]. Front Immunol,2023,14:1165507.
[28] Yao J,Wang J,Xu Y,et al. CDK9 inhibition blocks the initiation of PINK1-PRKN-mediated mitophagy by regulating the SIRT1-FOXO3-BNIP3 axis and enhances the therapeutic effects involving mitochondrial dysfunction in hepatocellular carcinoma[J]. Autophagy,2022,18(8):1879-1897.
[29] Vuong JT,Stein-Merlob AF,Cheng RK,et al. Novel Therapeutics for Anthracycline Induced Cardiotoxicity[J]. Front Cardiovasc Med,2022,9:863314.
[30] ]Yang M,Abudureyimu M,Wang X,et al. PHB2 ameliorates Doxorubicin-induced cardiomyopathy through interaction with NDUFV2 and restoration of mitochondrial complex Ⅰ function [J]. Redox Biol,2023,65:102812.
[31] Liang X,Wang S,Wang L,et al. Mitophagy inhibitor liensinine suppresses doxorubicin-induced cardiotoxicity through inhibition of Drp1-mediated maladaptive mitochondrial fission[J]. Pharmacol Res,2020,157:104846.
[32] ]Li S,Liu H,Lin Z,et al. Isoorientin attenuates doxorubicin-induced cardiac injury via the activation of MAPK,Akt,and Caspase-dependent signaling pathways[J]. Phytomedicine,2022,101:154105.
[33] Arinno A,Maneechote C,Khuanjing T,et al. Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics[J].?Biochem Pharmacol,2023,208:115414.
[34] Khuanjing T,Ongnok B,Maneechote C,et al. Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis[J]. Pharmacol Res,2021,173:105882.
[35] Qin Y,Lv C,Zhang X,et al. Neuraminidase1 inhibitor protects against doxorubicin-induced cardiotoxicity?via?suppressing Drp1-dependent mitophagy[J]. Front Cell Dev Biol,2021,9:802502.
[36] Zhuang X,Sun X,Zhou H,et al. Klotho attenuated doxorubicin-induced cardiomyopathy by alleviating dynamin-related protein 1-mediated mitochondrial dysfunction[J]. Mech Ageing Dev,2021,195:111442.
相似文献/References:
[1]张国贤 彭瑜 张钲.冠状动脉内皮细胞线粒体损伤在心肌梗死中的研究进展[J].心血管病学进展,2023,(3):203.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.003]
ZHANG Guoxian,PENG Yu,ZHANG Zheng.Mitochondrial Injury of Coronary Endothelial Cells in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2023,(4):203.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.003]
[2]王鹏 王鑫 张瑶 张经泽 贺世豪 李瑾.内质网应激在阿霉素心脏毒性中作用的研究进展[J].心血管病学进展,2023,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
WANG Peng,WANG Xin,ZHANG Yao,et al.Role of Endoplasmic Reticulum Stress?n the Cardiotoxicity of Doxorubicin[J].Advances in Cardiovascular Diseases,2023,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
[3]李登科 张伟 黄从新.SIRT1介导的信号通路在阿霉素诱导心脏毒性中的作用机制[J].心血管病学进展,2024,(3):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
LI Dengke,ZHANG Wei,HUANG Congxin.The Mechanisms of SIRT1-Mediated Signal Pathway in Doxorubicin-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(4):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
[4]李登科 张伟 黄从新.黄芩苷通过调节Nrf2/HO-1信号通路减轻阿霉素诱导的H9c2细胞毒性[J].心血管病学进展,2024,(5):457.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.017]
LI Dengke,ZHANG Wei,HUANG Congxin.Baicalin Reduces Doxorubicin Induced H9c2 Cell Toxicity by Regulating the Nrf2/HO-1 Signaling Pathway[J].Advances in Cardiovascular Diseases,2024,(4):457.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.017]
[5]沈鐲钰 黄丹 赵淑红 马振国.卡格列净对阿霉素所致心肌细胞损伤的作用及机制研究[J].心血管病学进展,2025,(3):272.[doi:10.16806/j.cnki.issn.1004-3934.2025.03.017]
SHEN Zheyu,HUANG Dan,ZHAO Shuhong,et al.Canagliflozin’s Role in Ameliorating Doxorubicin-Induced Injury in Cardiomyocytes[J].Advances in Cardiovascular Diseases,2025,(4):272.[doi:10.16806/j.cnki.issn.1004-3934.2025.03.017]